Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.
HLA peptides
chronic lymphocytic leukemia
immunopeptidomics
immunotherapy
mass spectrometry
peptide vaccines
peptide warehouse
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
05
2021
accepted:
24
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition of naturally presented antigens derived from mutated and unmutated gene products on human leukocyte antigens, and represent a promising low-side-effect concept for cancer treatment. So far, the broad application of peptide vaccines in cancer patients is hampered by challenges of time- and cost-intensive personalized vaccine design, and the lack of neoepitopes from tumor-specific mutations, especially in low-mutational burden malignancies. In this study, we developed an immunopeptidome-guided workflow for the design of tumor-associated off-the-shelf peptide warehouses for broadly applicable personalized therapeutics. Comparative mass spectrometry-based immunopeptidome analyses of primary chronic lymphocytic leukemia (CLL) samples, as representative example of low-mutational burden tumor entities, and a dataset of benign tissue samples enabled the identification of high-frequent non-mutated CLL-associated antigens. These antigens were further shown to be recognized by pre-existing and
Identifiants
pubmed: 34305947
doi: 10.3389/fimmu.2021.705974
pmc: PMC8297687
doi:
Substances chimiques
Antigens, Neoplasm
0
Epitopes
0
Peptides
0
Banques de données
ClinicalTrials.gov
['NCT04688385']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
705974Informations de copyright
Copyright © 2021 Nelde, Maringer, Bilich, Salih, Roerden, Heitmann, Marcu, Bauer, Neidert, Denzlinger, Illerhaus, Aulitzky, Rammensee and Walz.
Déclaration de conflit d'intérêts
H-GR is shareholder of Immatics Biotechnologies GmbH, Synimmune GmbH, and Curevac AG, and holds a patent application on an adjuvant, XS15. AN, H-GR, and JW are listed as inventors on patents related to peptides described in this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2020 Mar;34(3):787-798
pubmed: 31628428
Methods Mol Biol. 2019;1988:123-136
pubmed: 31147937
Cancer J. 2017 Mar/Apr;23(2):102-107
pubmed: 28410297
Mol Cell Proteomics. 2021 Feb 8;20:100022
pubmed: 33583769
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Blood Cells. 1987;12(2):471-83
pubmed: 2441780
Blood. 2006 Jan 15;107(2):628-36
pubmed: 16179369
Neuro Oncol. 2019 Feb 19;21(3):348-359
pubmed: 30500939
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90
pubmed: 15365188
Oncoimmunology. 2015 Jul 01;5(5):e1065369
pubmed: 27467910
J Clin Invest. 2016 Dec 1;126(12):4690-4701
pubmed: 27841757
Immunogenetics. 2009 Jan;61(1):1-13
pubmed: 19002680
Mol Cell Proteomics. 2007 Jan;6(1):102-13
pubmed: 17074750
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Blood. 2015 Mar 26;125(13):2079-86
pubmed: 25662332
Nat Med. 2012 Aug;18(8):1254-61
pubmed: 22842478
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
Nat Commun. 2013;4:1616
pubmed: 23511480
BMC Genomics. 2008 Oct 16;9:488
pubmed: 18925949
Methods Mol Biol. 2007;409:75-93
pubmed: 18449993
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Clin Immunol. 2010 Apr;135(1):55-62
pubmed: 20015695
J Immunother. 2004 May-Jun;27(3):184-90
pubmed: 15076135
Blood. 2019 Feb 7;133(6):550-565
pubmed: 30530751
J Exp Med. 2008 Mar 17;205(3):595-610
pubmed: 18299400
Nat Commun. 2020 Jan 31;11(1):661
pubmed: 32005826
Sci Transl Med. 2012 May 16;4(134):134ra62
pubmed: 22593175
Oncoimmunology. 2018 Feb 14;7(4):e1316438
pubmed: 29632711
Cancer Res. 2014 May 15;74(10):2663-8
pubmed: 24778417
Oncoimmunology. 2016 Oct 20;5(12):e1242544
pubmed: 28123879
J Am Soc Mass Spectrom. 1994 Nov;5(11):976-89
pubmed: 24226387
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Immunology. 2018 Jul;154(3):331-345
pubmed: 29658117
Leukemia. 2004 Jan;18(1):165-6
pubmed: 14603333
Cold Spring Harb Perspect Biol. 2018 Nov 1;10(11):
pubmed: 29254980
Sci Transl Med. 2021 Feb 17;13(581):
pubmed: 33597266
Cancer Immunol Immunother. 2007 Feb;56(2):227-36
pubmed: 16783578
Leukemia. 2015 Mar;29(3):647-59
pubmed: 25092142
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
Genome Med. 2020 Mar 30;12(1):32
pubmed: 32228647
Lancet Oncol. 2016 Nov;17(11):1599-1611
pubmed: 27720136
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
Leukemia. 2019 Feb;33(2):518-558
pubmed: 30209402
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Proteomics. 2018 Jun;18(12):e1700465
pubmed: 29786170
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9
pubmed: 20547850
Semin Oncol. 2016 Apr;43(2):215-21
pubmed: 27040699
Blood. 2008 Feb 1;111(3):1357-65
pubmed: 17978170
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
J Immunother Cancer. 2019 Nov 15;7(1):307
pubmed: 31730025
Cancer Immunol Immunother. 2013 Sep;62(9):1485-97
pubmed: 23817722
Blood Cancer J. 2016 Apr 08;6:e411
pubmed: 27058226
JAMA Oncol. 2019 Jul 1;5(7):1043-1047
pubmed: 31021392
Acta Neuropathol. 2018 Jun;135(6):923-938
pubmed: 29557506
Front Immunol. 2020 Aug 28;11:1981
pubmed: 32983136
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Int J Cancer. 2016 Apr 1;138(7):1792-801
pubmed: 26519872
Clin Cancer Res. 2020 Sep 1;26(17):4511-4520
pubmed: 32439700
Cancer Immunol Immunother. 2019 Aug;68(8):1331-1340
pubmed: 31317218
Mol Cell Proteomics. 2015 Mar;14(3):658-73
pubmed: 25576301
J Immunol. 2017 Feb 15;198(4):1740-1747
pubmed: 28077600
BMC Bioinformatics. 2006 Mar 17;7:153
pubmed: 16545123
Oncoimmunology. 2016 Dec 7;6(2):e1252895
pubmed: 28344864
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Clin Cancer Res. 2011 Nov 1;17(21):6847-57
pubmed: 21918169
Cancer Manag Res. 2020 Oct 21;12:10411-10421
pubmed: 33116895
Nature. 1991 May 23;351(6324):290-6
pubmed: 1709722
Eur Urol. 2016 Jul;70(1):35-41
pubmed: 26782346
Ther Adv Med Oncol. 2019 Feb 19;11:1758835919830826
pubmed: 30815041
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9
pubmed: 20631300
Blood. 2015 Sep 3;126(10):1203-13
pubmed: 26138685
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Mol Cell Proteomics. 2014 Aug;13(8):2056-71
pubmed: 24623587
J Leukoc Biol. 2020 Oct;108(4):1435-1453
pubmed: 31430398
Nature. 2003 Feb 20;421(6925):852-6
pubmed: 12594515
Haematologica. 2017 Nov;102(11):e460-e464
pubmed: 28838995
Int J Cancer. 2012 Jul 1;131(1):140-9
pubmed: 21858810
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Clin Cancer Res. 2012 May 15;18(10):2943-53
pubmed: 22407833
J Immunol. 2018 Jul 15;201(2):792-803
pubmed: 29875150
Blood. 2005 Dec 15;106(13):4389-96
pubmed: 16131571
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
PLoS One. 2015 Nov 12;10(11):e0142310
pubmed: 26562161